...
首页> 外文期刊>Molecular imaging and biology: MIB : the official publication of the Academy of Molecular Imaging >Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.
【24h】

Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.

机译:小动物PET对修饰的PEG-苯胺基喹唑啉衍生物作为癌症中EGFR成像的潜在药物的评估。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The in vivo evaluation of three modified polyethylene glycol (PEG)-anilinoquinazoline derivatives labeled with (124)I, (18)F, and (11)C as potential positron emission tomography (PET) bioprobes for visualizing epidermal growth factor receptor (EGFR) in cancer using small animal PET. PROCEDURES: Xenograft mice with the human glioblastoma cell lines U138MG (lacking EGFR expression) and U87MG.wtEGFR (transfected with an overexpressing human wild-type EGFR gene) were used. Static and dynamic PET imaging was conducted for all three PEGylated compounds. Tumor necrosis, microvessel density, and EGFR levels were evaluated by histopathology and enzyme-linked immunosorbent assay. RESULTS: Nineteen animal models were generated (two U138MG, three U87MG, 14 with both U138MG and U87MG bilateral masses). In static images, a slight increase in tracer uptake was observed in tumors, but in general, there was no retention of tracer uptake over time and no difference in uptake between U138MG and U87MG masses. In addition, no significant uptake was demonstrated in dynamic scans of the (18)F-PEG tracer. No necrosis was present except in four animals. MVD was 9.6 and 48 microvessels/x400 field in the U138GM and U87GM masses, respectively (p = 0.00008). Similarly, the microvessel grades were generally higher in the U87GM group (p = 0.002). Total EGFR amount was higher in U87MG than U138MG masses (p = 0.001), but the ratio of activated (pY1068) to total EGFR did not differ (p = 0.95). CONCLUSIONS: PEGylated tracers labeled with (11)C, (124)I, and (18)F showed no significant difference in uptake between U138MG and U87MG glioblastoma xenograft mice. The tracer binding with EGFR could be influenced by activation of the tyrosine kinase portion of the receptor which was similar in U138MG and U87MG. Despite these results, these tracers should be investigated in animal models with mutant EGFR genes to determine whether aberrant receptor function plays a role in tumor uptake.
机译:目的:体内评估三种修饰的(124)I,(18)F和(11)C标记的聚乙二醇(PEG)-苯胺基喹唑啉衍生物作为潜在的正电子发射断层扫描(PET)生物探针,以可视化表皮生长因子受体( EGFR)在癌症中使用小动物PET。程序:使用具有人胶质母细胞瘤细胞系U138MG(缺乏EGFR表达)和U87MG.wtEGFR(转染过表达的人类野生型EGFR基因)的异种移植小鼠。对所有三种聚乙二醇化化合物进行静态和动态PET成像。通过组织病理学和酶联免疫吸附试验评估肿瘤坏死,微血管密度和EGFR水平。结果:生成了十九个动物模型(两个U138MG,三个U87MG,14个具有U138MG和U87MG的双侧肿块)。在静态图像中,在肿瘤中观察到示踪剂摄入量略有增加,但是通常,随时间的推移示踪剂摄入量没有保留,并且U138MG和U87MG肿块的摄取量没有差异。另外,在(18)F-PEG示踪剂的动态扫描中没有显示出明显的摄取。除了四只动物外,没有坏死。在U138GM和U87GM质量中,MVD分别为9.6和48微血管/ x400视野(p = 0.00008)。同样,U87GM组中的微血管等级通常较高(p = 0.002)。 U87MG中的总EGFR量高于U138MG质量(p = 0.001),但是活化的(pY1068)与总EGFR的比率没有差异(p = 0.95)。结论:标记有(11)C,(124)I和(18)F的聚乙二醇化示踪剂在U138MG和U87MG胶质母细胞瘤异种移植小鼠之间的摄取没有显着差异。示踪剂与EGFR的结合可能受受体酪氨酸激酶部分活化的影响,这与U138MG和U87MG中的相似。尽管有这些结果,仍应在具有突变EGFR基因的动物模型中研究这些示踪剂,以确定异常的受体功能是否在肿瘤摄取中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号